ライフサイエンスコーパス: multidrug

1 The multidrug ABC transporter, aadE, bacA, acrB, tetM, tetW,

2 would be suitable for treating many cases of multidrug and extensively drug-resistant tuberculosis.

3 a nodule-specific citrate transporter of the multidrug and toxic compound extrusion family, MtMATE67

4 The multidrug and toxin extrusion (MATE) transporter family

5 pressing need for new therapeutics to combat multidrug- and carbapenem-resistant bacterial pathogens.

6 key residues that are responsible for proton/multidrug antiport.

7 eability and persistent lung inflammation, a multidrug approach is required for efficacious CF therap

8 Tetracycline repressors (TetRs) modulate multidrug efflux pathways in several pathogenic bacteria

9 xins, including rhodamine (Rho), through the multidrug efflux protein MDR1 (also known as P-glycoprot

10 tructures of the Escherichia coli AcrAB-TolC multidrug efflux pump in resting and drug transport stat

11 We report that AcrAB-TolC, the main multidrug efflux pump of Escherichia coli, exhibits a st

12 al dynamics of the Campylobacter jejuni CmeB multidrug efflux pump.

13 ers function independently within the trimer.Multidrug efflux pumps significantly contribute for bact

14 proteins annotated as urea carboxylases and multidrug efflux pumps.

15 release rate, which may facilitate efficient multidrug efflux.

16 Multidrug-effluxing CD4(+)CD161(+) T cells also resisted

17 Multidrug-effluxing CD4(+)CD161(+) T cells were enriched

18 fitness cost in antibiotic-free medium, in a multidrug environment they promote the evolution of high

19 be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyc

20 Tetracycline, multidrug, macrolide-lincosamide-streptogramin, bacitrac

21 rgia, and Romania), 976 (75.1%) of which are multidrug or extensively drug resistant and 38.2%, 51.9%

22 one offers a new therapeutic perspective for multidrug refractory MM patients.

23 590 mg) or placebo once daily added to their multidrug regimen for 84 days.

24 ary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conver

25 Cancer cells can develop multidrug resistance (MDR) after prolonged exposure to c

26 bacterial resistance in hospitals, including multidrug resistance (MDR) and its association with seri

27 Multidrug resistance (MDR) attenuates the chemotherapy e

28 e amplification release of DOX and overcomes multidrug resistance (MDR) in cancer cells, producing a

29 RP1), which are involved in the formation of multidrug resistance (MDR) in cancer chemotherapy.

30 expression of P-glycoprotein (Pgp) increases multidrug resistance (MDR) in cancer, which greatly impe

31 Multidrug resistance (MDR) is a major cause of failure i

32 Multidrug resistance (MDR) is a major impediment to canc

33 f the promising strategies to overcome tumor multidrug resistance (MDR) is to deliver anticancer drug

34 This so-called multidrug resistance (MDR) may be reversed by selective,

35 Multidrug resistance (MDR) mediated by ATP-binding casse

36 However, multidrug resistance (MDR) of cancer cells has remained

37 The most common solid tumors show intrinsic multidrug resistance (MDR) or inevitably acquire such wh

38 ay of treatment; however, the development of multidrug resistance (MDR) restricts the efficacy of cur

39 lococcus aureus (MRSA) infection was 24% and multidrug resistance (MDR) was observed in 87% of the is

40 Conversely it is one of the main causes of multidrug resistance (MDR), being capable of effluxing m

41 d monoresistance, rifampicin monoresistance, multidrug resistance (MDR), fluoroquinolone-resistant mu

42 pe characterized by increased proliferation, multidrug resistance (MDR), invasion and metastasis.

43 f RND-type efflux pumps is a major factor in multidrug resistance (MDR), which makes these pumps impo

44 cer agents, leading to the phenomenon called multidrug resistance (MDR).

45 ins palliative because of the development of multidrug resistance (MDR).

46 Increased prevalence of multidrug resistance (MDR; 94% compared to 60% in layers

47 Deficiency of multidrug resistance 2 (mdr2), a canalicular phospholipi

48 Treatment of multidrug resistance 2 gene knockout (Mdr2(-/-) ) mice w

49 We have shown that partial hepatectomy in multidrug resistance 2 knockout (Mdr2(-/-) ) mice, a mod

50 inical success, followed by echinocandin and multidrug resistance among some Candida species, especia

51 st that the HpnN transporter is critical for multidrug resistance and cell wall remodeling in Burkhol

52 1 inhibitors, leading to further research on multidrug resistance and combination chemotherapy.

53 binding cassette (ABCC) transporters mediate multidrug resistance and ion conductance regulation.

54 ia is the epicentre of Plasmodium falciparum multidrug resistance and is facing high rates of dihydro

55 Bacterial efflux pumps confer multidrug resistance by transporting diverse antibiotics

56 antifungal stewardship is critical to limit multidrug resistance emergence.

57 Herein, using the mouse model of PSC (multidrug resistance gene 2 knockout), the hepatic knock

58 in administration on hepatic fibrosis in the multidrug resistance gene 2-knockout (Mdr2(-/-)) mouse m

59 e-spanning transporter PfMDR1 (P. falciparum multidrug resistance gene-1) as a determinant of parasit

60 of resistance to single drug classes and now multidrug resistance greatly hampers patient management.

61 We found multidrug resistance in 33 (9%) of 361 patients.

62 lications for understanding the emergence of multidrug resistance in bacteria.

63 s key position, ABC transporters can mediate multidrug resistance in cancer therapy and their dysfunc

64 specific ATP-dependent transporter linked to multidrug resistance in cancer; it plays important roles

65 Transcription factors MarR and MarA confer multidrug resistance in enteric bacteria by modulating e

66 Multidrug resistance is a global threat as the clinicall

67 Although multidrug resistance is uncommon, increasing reports of

68 demic C difficile ribotypes characterised by multidrug resistance might depend on antibiotic selectio

69 protein (Pgp) is an efflux pump important in multidrug resistance of cancer cells and in determining

70 The ATP-binding cassette (ABC) transporter multidrug resistance protein 1 (MRP1/ABCC1) is responsib

71 vity of two other major efflux transporters, multidrug resistance protein 2 and breast cancer resista

72 signaling cascade (phospholipase A2, COX-2, multidrug resistance protein 4, and G-protein-coupled pr

73 The multidrug resistance protein MRP1 is an ATP-binding cass

74 The multidrug resistance protein MRP1 is an ATP-driven pump

75 thiol/disulfide balance, greater extents of multidrug resistance protein-1 (MRP1) expression, and gr

76 ucture of heterodimeric Thermus thermophilus multidrug resistance proteins A and B (TmrAB), which not

77 on antiparallel homo- or heterodimeric small multidrug resistance proteins and examine whether the in

78 the expression of anti-apoptotic factors and multidrug resistance proteins.

79 upregulation of a single gene, encoding the multidrug resistance pump ABCB1.

80 operties of these two important molecules in multidrug resistance to chemotherapy.

81 esistance is uncommon, increasing reports of multidrug resistance to the azoles, echinocandins, and p

82 EmrE is a small multidrug resistance transporter found in Escherichia co

83 de that resembles that of Cam binding to the multidrug resistance transporter MdfA.

84 and was a highly sensitive substrate of the multidrug resistance transporter P-glycoprotein (P-gp).

85 eptible to most antibiotics, indicating that multidrug resistance was not the dominant reason for pre

86 esistant multidrug resistance, and extensive multidrug resistance with resistance to both a fluoroqui

87 resistance, second-line injectable-resistant multidrug resistance, and extensive multidrug resistance

88 ppropriate antibacterial use contributing to multidrug resistance, and increased morbidity and mortal

89 ce, we provide a framework for understanding multidrug resistance, mediated by analogous systems, acr

90 morphisms that occur before the emergence of multidrug resistance, particularly katG p.Ser315Thr, int

91 resistance (MDR), fluoroquinolone-resistant multidrug resistance, second-line injectable-resistant m

92 micking the ability of Salmonella to reverse multidrug resistance, we constructed a gold nanoparticle

93 cytometry and immunostaining have shown that multidrug resistance-associated protein 1 (MRP1) is prev

94 P-Glycoprotein (P-gp, ABCB1), multidrug resistance-associated protein 1 (MRP1, ABCC1),

95 th respect to potency and selectivity toward multidrug resistance-associated protein 1 (MRP1, ABCC1).

96 pecific therapeutics in the effort to combat multidrug resistance.

97 nfections that are difficult to treat due to multidrug resistance.

98 path leading to the emergence of high-level, multidrug resistance.

99 of tuberculosis incidence and prevalence of multidrug resistance.

100 ost critical mechanisms leading to bacterial multidrug resistance.

101 s, which may have important implications for multidrug resistance.

102 ibiotics for tackling the issue of bacterial multidrug resistance.

103 within phylogroup D-that is associated with multidrug resistance.

104 ified harbinger mutations that often precede multidrug resistance.

105 ay help to reduce the use of antibiotics and multidrug resistance.

106 sed on a lapatinib induced inhibition of the multidrug-resistance efflux transporter ABCB1, which is

107 Multidrug-resistance is a substantial threat to global e

108 In addition, other molecules targeting multidrug-resistance mechanisms, such as efflux pumps, a

109 to the case detection group (n=1439) and the multidrug-resistance risk group (n=314).

110 tuberculosis in the past 6 months or to the multidrug-resistance risk group if drugs for tuberculosi

111 in all analyses, whereas participants in the multidrug-resistance risk group were only included in an

112 ests are urgently needed for the analysis of multidrug resistant (MDR) and extensively drug resistant

113 ted for their antibacterial activity against multidrug resistant (MDR) Gram-positive and Gram-negativ

114 is, resistance categories were predefined as multidrug resistant (MDR), isoniazid resistant, rifampic

115 of ceftolozane-tazobactam resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa infecti

116 phenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited to Typhi isolates

117 y-onset infections; 66 isolates (50.0%) were multidrug resistant and, of 33 isolates tested for carba

118 transient hypoxia and the appearance of the multidrug resistant bacteria Staphylococcus simulans in

119 over new antibiotics or strategies to combat multidrug resistant bacteria, especially Gram-negative b

120 Multidrug resistant bacterial pathogens have become a se

121 illus fumigatus and emerging threats such as multidrug resistant Candida auris are also alarming.

122 losis cases and the second highest number of multidrug resistant cases worldwide.

123 ly used antibiotics, with 18 % ESBL and 36 % multidrug resistant Escherichia coli strains.

124 s in health care caused by the prevalence of multidrug resistant Gram-negative pathogens.

125 sub-Saharan Africa, and are associated with multidrug resistant HIV-1.

126 examined the evolutionary history of leading multidrug resistant hospital pathogens, the enterococci,

127 opment and hold promise for the treatment of multidrug resistant infections.

128 st planktonic and biofilm forms of different multidrug resistant microorganisms, we present here the

129 broad range of bacterial species, especially multidrug resistant ones.

130 iparum malaria due to their activity against multidrug resistant parasites.

131 e shown that induction of MarA can lead to a multidrug resistant phenotype at the population level.

132 iance often leads to therapeutic failure and multidrug resistant strain development.

133 compounds possess potent activity against a multidrug resistant strain of P. falciparum and arrest p

134 ones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains and carbapenem-resistant Ent

135 erial specific antibiotics, and treatment of multidrug resistant TB is longer.

136 frequent cause of such infections, is often multidrug resistant, and chronically colonizes a sizable

137 Although C auris is inherently multidrug resistant, other strains typically develop res

138 s, we characterize l(2)03659 as a Drosophila multidrug resistant-associated ABC transporter.

139 ream, or surgical site infection caused by a multidrug-resistant (cases) or -sensitive (controls) mic

140 An increase in the proportion of multidrug-resistant (MDR) 35B isolates has recently been

141 Multidrug-resistant (MDR) Acinetobacter baumannii is one

142 s are threatened by the increasing burden of multidrug-resistant (MDR) and extensively drug-resistant

143 Multidrug-resistant (MDR) and extensively drug-resistant

144 he highest incidences of DR-TB, particularly multidrug-resistant (MDR) and extensively drug-resistant

145 onsumption, incidence density of Candida and multidrug-resistant (MDR) bacteria bloodstream infection

146 Multidrug-resistant (MDR) bacterial infections are a ser

147 unctional CRISPR-Cas systems are absent from multidrug-resistant (MDR) Enterococcus faecalis, which o

148 Multidrug-resistant (MDR) gram-negative bacteria have in

149 se for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria.

150 Multidrug-resistant (MDR) infections are on the increase

151 sis that were due to inadequate treatment of multidrug-resistant (MDR) tuberculosis (i.e., acquired r

152 erculosis (LTBI) after contact to infectious multidrug-resistant (MDR) tuberculosis (TB) are lacking

153 rove treatment outcomes for individuals with multidrug-resistant (MDR) tuberculosis (TB).

154 al approach to assess recent transmission of multidrug-resistant (MDR) tuberculosis and identify pote

155 A novel, shorter-course regimen for treating multidrug-resistant (MDR) tuberculosis was recently reco

156 Multidrug-resistant (MDR) tuberculosis, "Ebola with wing

157 istance in patients with drug-susceptible or multidrug-resistant (nonXDR) tuberculosis strains.

158 In multivariate analysis, multidrug-resistant A. baumannii (odds ratio, 4.78; 95%

159 n-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (MDR-AB) wer

160 ion therapy is deployed for the treatment of multidrug-resistant Acinetobacter baumannii, as it can r

161 ycin-resistant enterococci, C difficile, and multidrug-resistant Acinetobacter.

162 ull gyrA and gyrB open reading frames in 240 multidrug-resistant and extensively drug-resistant tuber

163 es in the world, and the increased number of multidrug-resistant and extremely drug-resistant strains

164 Emerging multidrug-resistant bacteria are a challenge for modern

165 to ameliorate the development and spread of multidrug-resistant bacteria in cirrhosis.

166 ntions, including drugs and vaccines against multidrug-resistant bacteria such as Neisseria gonorrhoe

167 lator-associated pneumonia, and infection by multidrug-resistant bacteria were independently associat

168 With rapid emergence of multidrug-resistant bacteria, there is often a need to p

169 min antibiotics are used clinically to treat multidrug-resistant bacterial infections, but their poor

170 could serve as adjunctive treatments against multidrug-resistant bacterial infections.

171 , and have been proposed to be used to treat multidrug-resistant bacterial infections.

172 ed rational drug design approach to treating multidrug-resistant bacterial infections.

173 The risk of infections caused by multidrug-resistant bacterial pathogens increases with h

174 chanism when combined with AgNPs against the multidrug-resistant bacterium Salmonella typhimurium DT

175 criminate isoniazid-monoresistant cases from multidrug-resistant cases within 2 days.

176 mal-Pgp utilization enhances cytotoxicity to multidrug-resistant cells.

177 icrobial peptides displayed activity against multidrug-resistant clinical isolates of Escherichia col

178 with accurate identification of the pandemic multidrug-resistant clonal subgroup ST131-H30.

179 bial resistance was evaluated in an epidemic multidrug-resistant clone of K. pneumoniae (ST258).

180 e of serotype 35B disease and emergence of a multidrug-resistant clone reported in this issue of the

181 R genes associated with clinically important multidrug-resistant clones and epidemic plasmids, in Ame

182 n testing of fosfomycin was performed on 649 multidrug-resistant E. coli clinical isolates collected

183 tion or induction of UhpT but are rare among multidrug-resistant E. coli clinical strains.

184 l envelope; these include metallopeptidases, multidrug-resistant efflux (MDR) pumps, TonB-dependent r

185 iotics reduced selective pressures favouring multidrug-resistant epidemic ribotypes and was associate

186 iotics reduced selective pressures favouring multidrug-resistant epidemic ribotypes and was associate

187 Candida auris is an emerging multidrug-resistant fungal pathogen causing nosocomial a

188 efficacy of strategies for the prevention of multidrug-resistant gram-negative bacteria (MDR-GNB) in

189 olderia cepacia complex (Bcc) are a group of multidrug-resistant gram-negative bacteria rarely report

190 line of defence in serious infections due to multidrug-resistant Gram-negative bacteria, but their us

191 valuated against panels of tetracycline- and multidrug-resistant Gram-positive and Gram-negative path

192 pe 258 (ST258) are among the most widespread multidrug-resistant hospital-acquired pathogens.

193 Multidrug-resistant infection was associated with prior

194 eatment of several human diseases, including multidrug-resistant infections and genetic disorders.

195 sistance mutations shape the pathobiology of multidrug-resistant infections has the potential to driv

196 Multidrug-resistant infections were associated with rece

197 is a significant contributor to recalcitrant multidrug-resistant infections, especially in immunocomp

198 ealthcare worldwide as an important cause of multidrug-resistant infections.

199 ted bacterial pneumonia (HABP/VABP) is often multidrug-resistant infections.

200 y profiling their antiviral efficacy against multidrug-resistant influenza A viruses, in vitro drug r

201 The existence of multidrug-resistant influenza viruses, coupled with the

202 nya, and Tanzania (both sites combined), and multidrug-resistant iNTS was isolated in Burkina Faso (b

203 A clinical pathogenic multidrug-resistant isolate, E. coli 381, isolated from

204 sticity and speed of evolutionary changes in multidrug-resistant K. pneumoniae, demonstrating the hig

205 sing on the virulent, globally disseminated, multidrug-resistant lineage ST131.

206 to human cell lines, and are active against multidrug-resistant M. tuberculosis strains, indicating

207 public health efforts to limit the spread of multidrug-resistant malaria.

208 a significantly increased proportion of rare multidrug-resistant molds.

209 cond-line antitubercular drug used to combat multidrug-resistant Mtb strains.

210 ts inactive variant PRD25N, and an extremely multidrug-resistant mutant, PR20.

211 osis treatments, particularly in the case of multidrug-resistant Mycobacterium tuberculosis (Mtb).

212 Multidrug-resistant Neisseria gonorrhoeae is a top threa

213 compliance with prevention bundles impacted multidrug-resistant organism (MDRO) infections in Thai h

214 Mycobacterium abscessus is a fast-growing, multidrug-resistant organism that has emerged as a clini

215 SA) is the most common healthcare-associated multidrug-resistant organism.

216 have been implicated in the transmission of multidrug-resistant organisms (MDRO).

217 The emergence and spread of multidrug-resistant organisms (MDROs) across global heal

218 Infections by multidrug-resistant organisms (MDROs) are a global threa

219 bacterial infections including those due to multidrug-resistant organisms (MDROs).

220 Patients admitted to hospital can acquire multidrug-resistant organisms and Clostridium difficile

221 Multidrug-resistant organisms caused 56% of bacterial in

222 ect storm" for sustained endemicity of these multidrug-resistant organisms in Colombia.

223 h the aim to decrease selective pressure for multidrug-resistant organisms in order to preserve the u

224 strategies, may help mitigate the effect of multidrug-resistant organisms in the future.

225 he ability of bacterial pathogens, including multidrug-resistant organisms, to colonize and subsequen

226 m were identified, including infections with multidrug-resistant organisms.

227 on therapy are common and frequently involve multidrug-resistant organisms.

228 awback, the development of infections due to multidrug-resistant organisms.

229 countering the emergence and transmission of multidrug-resistant P. falciparum malaria.

230 Genetic tools to detect the multidrug-resistant parasites are needed.

231 eptibility testing (AFST) of the potentially multidrug-resistant pathogen Candida glabrata against an

232 Candida auris is an emerging, often multidrug-resistant pathogen with important public healt

233 r empiric antimicrobial therapy against this multidrug-resistant pathogen.

234 The emerging multidrug-resistant pathogenic yeast Candida auris repre

235 We will focus on 3 important multidrug-resistant pathogens that are notoriously probl

236 However, for multidrug-resistant pathogens, demonstration of superior

237 ibit potent antimicrobial activities against multidrug-resistant pathogens.

238 ons, antibiotic resistance, and particularly multidrug-resistant profiles, is certainly of paramount

239 Infections by multidrug-resistant Pseudomonas aeruginosa (MDRPa) are a

240 ith the adhesin MAM7 to a burn infected with multidrug-resistant Pseudomonas aeruginosa substantially

241 Falling 4C use predicted rapid declines in multidrug-resistant ribotypes R001 and R027.

242 Multidrug-resistant S Typhi was isolated in Ghana, Kenya

243 The case illustrates clinical challenges of multidrug-resistant S.

244 eus, methicillin-resistant S. aureus (MRSA), multidrug-resistant S. aureus (MDRSA), absence of scn (p

245 With the worldwide emergence of the multidrug-resistant species Candida auris, identificatio

246 Children with multidrug-resistant sporadic disease show better renal s

247 otic resistance spreads among bacteria, with multidrug-resistant staphylococci and streptococci infec

248 h antibacterial activity against an array of multidrug-resistant staphylococci.

249 The emergence of multidrug-resistant strains is an increasing danger to p

250 ed by the HIV/AIDS pandemic and emergence of multidrug-resistant strains of Mycobacterium tuberculosi

251 t in antimicrobial activity observed against multidrug-resistant strains of Pseudomonas aeruginosa an

252 multiple M. tuberculosis strains (including multidrug-resistant strains).

253 gainst Mycobacterium tuberculosis, including multidrug-resistant strains, and some species of nontube

254 uctions into Africa, all from Asia, involved multidrug-resistant sublineages that replaced antibiotic

255 have great potential to limit the spread of multidrug-resistant tuberculosis (MDR-TB) and extensivel

256 It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year.

257 patients successfully treated for pulmonary multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russ

258 Multidrug-resistant tuberculosis (MDR-TB) is an importan

259 Less than 30% of multidrug-resistant tuberculosis (MDR-TB) patients are c

260 Multidrug-resistant tuberculosis (MDR-TB), caused by dru

261 e the etiology of "hotspots" of concentrated multidrug-resistant tuberculosis (MDR-tuberculosis) risk

262 focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacte

263 improve treatment outcomes for patients with multidrug-resistant tuberculosis and prevent the spread

264 ing percentage reduction in the incidence of multidrug-resistant tuberculosis by 2024 compared with c

265 idrug-resistant tuberculosis will be primary multidrug-resistant tuberculosis compared with only 15%

266 ovements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number

267 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

268 en has potential to substantially lessen the multidrug-resistant tuberculosis epidemic, but this effe

269 rge public health and societal implications, multidrug-resistant tuberculosis has been long regarded

270 ns in the primary analysis, the incidence of multidrug-resistant tuberculosis in 2024 would be 3.3 (9

271 est number of patients with tuberculosis and multidrug-resistant tuberculosis in the world.

272 of isoniazid resistance, a 152% increase in multidrug-resistant tuberculosis incidence, a 242% incre

273 rculosis, and a 275% increase in the risk of multidrug-resistant tuberculosis infection.

274 ay, 2016, WHO endorsed a 9 month regimen for multidrug-resistant tuberculosis that is cheaper and pot

275 By 2032, an estimated 85% of multidrug-resistant tuberculosis will be primary multidr

276 ence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a 275% increase in

277 n settings with more ongoing transmission of multidrug-resistant tuberculosis, but results were other

278 d-resistant tuberculosis is more common than multidrug-resistant tuberculosis, it has been much less

279 he public sector contributed 87% of acquired multidrug-resistant tuberculosis, related to irregular a

280 h all-cause mortality among US patients with multidrug-resistant tuberculosis.

281 th a potential for immunotherapy in treating multidrug-resistant tuberculosis.

282 for the development of novel drugs to tackle multidrug-resistant tuberculosis.

283 ensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of acces

284 Broad-spectrum antibiotics for recurrent multidrug-resistant urinary tract infections (UTIs) disr

285 tion, and only two cases of infection with a multidrug-resistant virus have been reported under adequ

286 Candida auris, a multidrug-resistant yeast that causes invasive infection

287 ith the industrial production of eggs and of multidrug-resistant, bloodstream-invasive infection in A

288 Acinetobacter pittii are a frequent cause of multidrug-resistant, healthcare-associated infections.

289 increased transmission risk; however, having multidrug-resistant-A. baumannii and specific healthcare

290 a potential selective advantage possessed by multidrug-resistant-A. baumannii in this environment and

291 Importantly, therapeutic advances in multidrug systemic therapy and radiation therapy have al

292 which owed much to WHO and the donors of the multidrug therapy components, prompted WHO in 1991 to se

293 The patient was started on WHO multidrug therapy for paucibacillary leprosy along with

294 obal implementation of this highly effective multidrug therapy took about 15 years.

295 rmat, treatment of TB requires six months of multidrug therapy with a mixture of broad spectrum and m

296 In 1985, 5.3 million patients were receiving multidrug therapy; by 1991, this figure had decreased to

297 yl-4-hydroxyquinoline N-oxide (HQNO) induces multidrug tolerance in S. aureus through respiratory inh

298 RATIONALE: Lengthy, multidrug, toxic, and low-efficacy regimens limit manage

299 onally important switch loop of the trimeric multidrug transporter AcrB separates the access and deep

300 GF-R) activation and the expression of ABCC1 multidrug transporter gene, thus contributing to tumor c

301 P-glycoprotein (P-gp) is a multidrug transporter that uses energy from ATP hydrolys

302 gemcitabine effectiveness by down-regulating multidrug transporters as well by converting gemcitabine

303 engthens the case for EGCG as a candidate in multidrug treatment of persistent biofilm infections.